Event

Monoclonal Antibodies and Their Interference with Immunohematology Testing (23EL-818)

Please note: AABB reserves the right to make updates to this program.

Wednesday, March 29, 2023
2:00 – 3:00 PM Eastern Time
Program Number: 23EL-818

  • Educational Track: Technical/Clinical
  • Topics: Blood Donation & Collection, Patient Transfusion
  • Intended Audience: Directors, Facilities that perform molecular testing, Hospital Blood Banks, Hospitals, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research Scientists, Residents/Fellows, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
  • Teaching Level: Advanced, Intermediate
  • Director/Moderator: Huy P. Pham, MD, MPH, Medical Director and Adjunct Professor of Medicine, National Marrow Donor Program (NMDP), Seattle, WA
    Speakers:

    • Randall W. Velliquette, SBB(ASCP)CM, Chief Immunohematologist and Technical Manager, New York Blood Center Enterprises, New York, NY
    • Lance A. Williams III, MD, Medical Director Therapeutic Apheresis, Staff Physician in Transfusion Medicine, Mayo Clinic, Phoenix, AZ
  • Program Description

    Therapeutic monoclonal antibodies are increasingly being used in the treatment of patients with a variety of conditions including malignancy, infection, and inflammatory diseases. The interference caused by monoclonal antibodies in clinical laboratory testing is an emerging concern that requires both recognition and the development of appropriate solutions to mitigate. For example, anti-CD38 and anti-CD47 can cause interference in with routine pre-transfusion testing in the blood bank and thus, might affect the turn-around time in identification of possible alloantibodies and potential delay in compatibility testing for patients requiring blood transfusion. Therefore, it is essential for transfusion services to be aware of such therapy being administered to patients and to develop solutions to overcome this interference to enhance patient safety. This program will provide an introduction to monoclonal antibody therapy, especially ones that may cause interference in serological testing. The interference in blood bank testing caused by these drugs will be described, along with possible solutions to overcome the interference using currently available techniques. Finally, examples of how transfusion services handle such challenges in conjunction with the clinical service will be reviewed.

    Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Review different monoclonal antibodies that may have interference with immunohematology testing and their clinical indications.
    • Outline the potential interference of monoclonal antibodies with routine blood bank testing and methods to resolve such interference.
    • Provide examples of protocols on how transfusion services handle such challenges to provide patients with the best products possible, while also accounting for inventory challenges.

    Registration

    Registration includes access to both the live and on-demand version of this eCast.

    If you are a facility interested in participating in this eCast, simply complete the Group Viewing registration form and AABB will provide detailed instructions to share with your team approximately one week prior to the live program (each team member to register for the program utilizing a promocode). For single viewers, simply click on the Register button below to register.

    Please note: registration for the live eCast will close 1 hour prior to the eCast start time. If you register after this time you will receive access to the on-demand eCast when it is available.

    Single Viewer Register
    Group Viewing Register

    Continuing Education Credit

    This activity is eligible for one (1) continuing education credit/contact hour for Physicians, Nurses (including California-based nursing professionals through CBRN), California Lab Personnel, Florida Lab Personnel and General Participation credit. AABB reserves the right to reduce or increase the number of credits granted based on the final activity duration. For more information on each credit type please visit our Continuing Education Credits webpage.

    There is no financial support for this activity.

    Jointly Accredited Provider

    In support of improving patient care, this activity has been planned and implemented by the Association for the Advancement of Blood & Biotherapies (AABB) and CME Outfitters, LLC. CME Outfitters LLC. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians (ACCME): CME Outfitters, LLC, designates this live activity for a maximum of one (1) AMA PRA Category 1 CreditTM. CME Outfitters, LLC, designates this enduring activity for a maximum of one (1) AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Claiming Credit
    Live Activity - Upon completion of the live activity, you will receive instructions to complete your evaluation, which is necessary to claim credit and receive your certificate of attendance/completion (credit must be claimed by the date provided in the instructions). The evaluation can be found by logging into the AABB Education Platform.

    Enduring Activity - Once the enduring (on-demand) program is available, you will receive instructions to access the AABB Education Platform. Upon completion of viewing the enduring activity, you will need to complete the evaluation, which is necessary to claim credit and receive your certificate of completion (credit must be claimed by the date provided in the AABB Education Platform).

    Program & Credit Expiration Dates:

    • Live Activity Program Date: March 29, 2023; Credit Expiration Date: April 29, 2023
    • Enduring Activity Program Dates: March 29, 2023 – March 28, 2026; Credit Expiration Date: March 28, 2026

    Disclosure Declaration

    It is the policy of CME Outfitters, LLC, and the Association for the Advancement of Blood & Biotherapies to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that the presence of such relationships will have a negative impact on the presentations.

    Disclosures for the planners of this event can be found here. Disclosures for the program faculty, peer reviewers, and CME Outfitters, LLC. personnel are provided at the beginning of the program.

    Faculty Biographies

    Dr. Huy P. Pham is the Medical Director at the National Marrow Donor Program (NMDP) Apheresis Collection Center in Seattle, which is the first apheresis center that is owned and operated by the NMDP. He is also an adjunct professor of Medicine at the Medical College of Wisconsin, which is the home of the academic and research department of the NMDP. Dr. Pham specializes in Apheresis and Transfusion Medicine and is actively involved in many committees at the AABB and ASFA.

    Randall W. Velliquette is the Chief Immunohematologist and Technical Manager in the Laboratory of Immunohematology and Genomics at the New York Blood Center (NYBC). Prior to the NYBC, Randall worked in the Transfusion Services department in a large academic hospital in Manhattan. Randall is actively involved in many AABB committees.

    Dr. Lance Williams has served a Consultant Physician at the Mayo Clinic in Phoenix, Arizona since November of 2019. He is currently the medical director of therapeutic apheresis, but also serves in a consulting capacity for blood bank, coagulation, the human cellular therapy lab, and the core laboratory. From 2013 to 2019, he was a tenured associate professor at the University of Alabama at Birmingham (UAB). In his time there, he held many titles including the following: medical director of therapeutic apheresis; medical director of special coagulation; medical director and CLIA lab director at 5 community hospitals; and, associate residency program director. During his time at UAB, he earned 6 teaching awards from both the Pathology residency program and the medical school curriculum.